Polycystic Kidney Disease News and Research RSS Feed - Polycystic Kidney Disease News and Research

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million. [More]
UC Santa Barbara professor develops novel therapeutic strategy for PKD

UC Santa Barbara professor develops novel therapeutic strategy for PKD

For the 12 million people worldwide who suffer from polycystic kidney disease (PKD), an inherited disorder with no known cure, a new treatment option may be on the horizon. [More]
New technique slows progression of polycystic kidney disease in mice

New technique slows progression of polycystic kidney disease in mice

A new technique for treating polycystic kidney disease has been identified by researchers based at the UCL Institute of Child Health. Published in the Journal of the American Society of Nephrology, the treatment, which involves targeting tiny blood and lymphatic vessels inside the kidneys, is shown to improve renal function and slow progression of disease in mice. [More]
Manchester, UCL researchers discover new technique for treating polycystic kidney disease

Manchester, UCL researchers discover new technique for treating polycystic kidney disease

A new technique for treating polycystic kidney disease has been identified by researchers at The University of Manchester and UCL. [More]

First European approval of drug to treat genetic kidney disease ADPKD

Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has granted marketing authorisation for JINARC® (tolvaptan) for the treatment of ADPKD in adults who have chronic kidney disease (CKD) stage one to three at initiation of treatment with evidence of rapidly progressing disease [More]
Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases. It's also one of the most common reasons that people require dialysis or transplantation... [More]
DFG selects 10 researchers to receive 2015 Heinz Maier-Leibnitz Prize

DFG selects 10 researchers to receive 2015 Heinz Maier-Leibnitz Prize

This year's recipients of the most important prize for early career researchers in Germany have been announced. The selection committee, appointed by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) and the German Federal Ministry of Education and Research (BMBF), has chosen ten researchers, five women and five men, to receive the 2015 Heinz Maier-Leibnitz Prizes. [More]
Today’s “World Kidney Day” promotes kidney health for all

Today’s “World Kidney Day” promotes kidney health for all

Recent surveys have shown that the general public’s understanding about what our kidneys do and what the risk factors for kidney disease are, is astoundingly poor. In the UK, five leading kidney charities are joining forces in the campaign “Kidney Charities Together,” which calls for urgent action to be taken to raise awareness of kidney disease. [More]
EMA's CHMP backs JINARC (tolvaptan) for autosomal dominant polycystic kidney disease

EMA's CHMP backs JINARC (tolvaptan) for autosomal dominant polycystic kidney disease

Otsuka Pharmaceutical Co., Ltd. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended JINARC (tolvaptan) for approval. [More]

Brandeis University researchers capture highest resolution images of cilia ever

Cilia, the cell's tails and antennas, are among the most important biological structures. They line our windpipe and sweep away all the junk we inhale; they help us see, smell and reproduce. When a mutation disrupts the function or structure of cilia, the effects on the human body are devastating and sometimes lethal. [More]
NIH study finds limited kidney benefit from more rigorous blood pressure treatment

NIH study finds limited kidney benefit from more rigorous blood pressure treatment

Using two drugs was no more effective than a single drug in slowing disease progression in people with autosomal dominant polycystic kidney disease (ADPKD), according to two studies funded by the National Institutes of Health. One of the studies also showed that rigorous blood pressure treatment slowed growth of kidney cysts, a marker of ADPKD, but had little effect on kidney function compared to standard blood pressure treatment. [More]
Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka Pharmaceutical Development & Commercialization, Inc., announced today that patient enrollment has begun for a new Phase 3b study of tolvaptan for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common, life-threatening, inherited genetic kidney disorder. [More]
Study: Pravastatin slows down growth of kidney cysts in children, young adults with ADPKD

Study: Pravastatin slows down growth of kidney cysts in children, young adults with ADPKD

Results from a study by University of Colorado School of Medicine researchers show that pravastatin, a medicine widely used for treatment of high cholesterol, also slows down the growth of kidney cysts in children and young adults with autosomal dominant polycystic kidney disease (ADPKD). [More]
3 pioneering cell biologists win 2014 E.B. Wilson Medal from American Society for Cell Biology

3 pioneering cell biologists win 2014 E.B. Wilson Medal from American Society for Cell Biology

If cells were cars, then the three pioneering cell biologists just named winners of the 2014 E.B. Wilson Medal, the highest scientific honor of the American Society for Cell Biology, helped write the essential parts list. [More]
Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Otsuka Pharmaceutical Co., Ltd. today announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Samsca (generic name: tolvaptan) has been approved in Japan in 7.5-mg and 15-mg tablet forms for extended use for the additional indication of ADPKD. Also, the new dosage form of 30-mg Samsca tablets has received approval for the indication of ADPKD. [More]
Scientists discover that natural product in grapefruit can prevent kidney cysts

Scientists discover that natural product in grapefruit can prevent kidney cysts

Scientists at Royal Holloway, University of London, have discovered that a natural product found in grapefruit can prevent kidney cysts from forming. [More]
Researchers discover protein required for growth of hair-like structures on cell surfaces

Researchers discover protein required for growth of hair-like structures on cell surfaces

A team of researchers from Penn State University and the University of California has discovered a protein that is required for the growth of tiny, but critical, hair-like structures called cilia on cell surfaces. [More]
EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD). [More]
Holiday reads: Squabbling families, the psychology of Santa, holiday stress and chocolate chip cookies

Holiday reads: Squabbling families, the psychology of Santa, holiday stress and chocolate chip cookies

[T]his time of year the Internet is ripe with lists on how to avoid or mitigate family conflicts. At big gatherings, familiarity may not always breed contempt, but it sure can breed festering emotional wounds. Leonard Felder, a Los Angeles psychologist, has found that about three-quarters of us have at least one family member who annoys us. But why is it that the same minor jabs and annoying tics that are harmless coming from friends prompt epic screaming matches when uttered by relatives? ... Here are four theories as to why our families drive us nuts, and it would be nice of you to pay attention for once in your life (Olga Khazan, 12/23). [More]
Scientists at Salk Institute develop novel platform to study kidney diseases

Scientists at Salk Institute develop novel platform to study kidney diseases

​Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology. [More]
Advertisement
Advertisement